Sexual Behavior, Human Papillomavirus Type 16 (HPV 16) Infection, and HPV 16 Seropositivity
- 1 March 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 29 (3) , 182-187
- https://doi.org/10.1097/00007435-200203000-00009
Abstract
Background Sexual behaviors have been linked to seropositivity for human papillomavirus (HPV) but not with the magnitude of the seroreactivity. Goals The objective of this analysis was to examine the association of sexual behavior, cervical HPV 16 DNA positivity at enrollment (past) and at diagnosis (current), and other potential determinants with the likelihood and magnitude of HPV 16 seropositivity at diagnosis. Study Design With use of stored specimens from an incidence case–control study at Kaiser Permanente (Portland, OR), women were tested for seroreactivity to HPV 16 by enzyme-linked immunosorbent assay with virus-like particles at diagnosis and were tested for past and concurrent cervical HPV 16 DNA positivity with MY09/MY11 L1 consensus primer PCR. Questionnaire data were used to ascertain past sexual behavior. Results Increased lifetime number of sex partners (PTrend < 0.001), past HPV 16 DNA positivity (odds ratio = 6.9; 95% confidence interval = 1.5–31), and a current cytologic diagnosis (PTrend < 0.03) were independently associated with HPV 16 seropositivity. Among the seropositive, only lifetime number of sex partners (PTrend < 0.001) and past HPV 16 DNA positivity (P = 0.003) were independently associated with mean signal strength (optical density) in an age-adjusted analysis. Women negative for past and concurrent HPV 16 DNA had a significant trend of increasing optical densities associated with greater numbers of lifetime partners (PTrend < 0.001). Conversely, the mean signal strength for those women who were ever HPV 16 DNA–positive during the study did not depend on lifetime numbers of sex partners (PTrend = 0.36). Conclusions HPV 16 seropositivity is a surrogate for past HPV 16 infection. Circulating levels of antibodies to HPV 16 may reflect recent HPV 16 infection or the frequency of past HPV 16 infection.Keywords
This publication has 18 references indexed in Scilit:
- Human papillomavirus and cancer: the epidemiological evidenceJournal of Clinical Virology, 2000
- Seroreactivity to Human Papillomavirus Types 16, 18, 31, and 45 Virus‐Like Particles in a Case‐Control Study of Cervical Squamous Intraepithelial LesionsThe Journal of Infectious Diseases, 1999
- Human papillomavirus is a necessary cause of invasive cervical cancer worldwideThe Journal of Pathology, 1999
- Detection of Human Papillomavirus DNA in Cytologically Normal Women and Subsequent Cervical Squamous Intraepithelial LesionsJNCI Journal of the National Cancer Institute, 1999
- Epidemiologic Determinants of Seroreactivity to Human Papillomavirus (HPV) Type 16 Virus-Like Particles in Cervical HPV-16 DNA--Positive and --Negative WomenThe Journal of Infectious Diseases, 1996
- Evaluation of Seroreactivity to Human Papillomavirus Type 16 Virus-like Particles in an Incident Case-Control Study of Cervical NeoplasiaThe Journal of Infectious Diseases, 1995
- Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide PerspectiveJNCI Journal of the National Cancer Institute, 1995
- A Virus-Like Particle Enzyme-Linked Immunosorbent Assay Detects Serum Antibodies in a Majority of Women Infected With Human Papillomavirus Type 16JNCI Journal of the National Cancer Institute, 1994
- Persistence of Type-Specific Human Papillomavirus Infection among Cytologically Normal WomenThe Journal of Infectious Diseases, 1994
- Epidemiologic Evidence Showing That Human Papillomavirus Infection Causes Most Cervical Intraepithelial NeoplasiaJNCI Journal of the National Cancer Institute, 1993